Antiretroviral activity and cytotoxicity of novel zidovudine (AZT) derivatives and the relation to their chemical structure

International Journal of Antimicrobial Agents

Volumn 20, Issue 4, 2002, Pages 282-288

  Turk, Gabriela ^a   Moroni, Guillermo ^b   Pampuro, Sandra ^a   Brión, Margarita C ^b   Salomón, Horacio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Antiretroviral activity; Cytotoxicity; HIV; Zidovudine analogues

Indexed keywords

3' AZIDO 3' DEOXY 5' (2 ISONICOTINOYL)THYMIDINE; 3' AZIDO 3' DEOXY 5' (2 OXALYL) N ISOLEUCINETHYMIDINE; 3' AZIDO 3' DEOXY 5' (2 OXALYL) N PHENYLALANINETHYMIDINE; 3' AZIDO 3' DEOXY 5' (2 OXALYL) N VALINETHYMIDINE; 3' AZIDO 3' DEOXY 5' (2 OXALYL)THYMIDINE ACID; 3' AZIDO 3' DOEXY 5' (2 OXALYL) N LEUCINETHYMIDINE; 5 CHLORO 6 HYDROXY 5,6 DIHYDRO 3' AZIDO 3' DEOXYTHYMIDINE; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CELL CULTURE; DRUG ANALYSIS; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; HIV-1; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; ZIDOVUDINE;

EID: 0036774972     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00191-7     Document Type: Article

References (23)

1. Weller I.V., Williams I.G. ABC of AIDS. Antiretroviral drugs. Br. Med. J. 322:2001;1350-1354.
2. Weller I.V., Williams I.G. ABC of AIDS. Antiretroviral drugs. Br. Med. J. 322:2001;1410-1412.
3. De Clercq E. Reverse transcriptase inhibitors as anti-HIV drugs. Unger R.E., Kreuter J., Rübsamen-Waigmann H., Antiviral against AIDS. 2000;Marcel Dekkers, New York.
4. Kukhanova M., Krayevsky A., Prusoff W., Cheng Y.C. Design of anti-HIV compounds: from nucleoside to nucleoside 5′-triphosphate analogues. Problems and perspectives. Curr. Pharm. Des. 6:2000;585-589.
5. Parang K., Wiebe L.I., Knaus E.E. Novel approaches for designing 5′-O-ester prodrugs of 3′-azido-2′,3′-dideoxythymidine (AZT). Curr. Med. Chem. 7:2000;995-1039.
6. Larder B.A., Darby G., Richman D.D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 243:1989;1731-1734.
7. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science. 246:1989;1155-1158.
8. Brener B., Wainberg M.A., Salomon H., et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int. J. Antimicrob. Agents. 16:2000;429-434.
9. Parang K., Wiebe L.I., Knaus E.E. Synthesis, in vitro anti-human immunodeficiency virus structure-activity relationships and biological stability of 5′-myristoyl analogue derivatives of 3′-azido-2′,3′-dodeoxythymidine (AZT) as potential prodrugs. Antivir. Chem. Chemother. 9:1998;311-323.
10. Henin Y., Gouyette C., Schwartz O., Debouzy J.C., Neumann J.M., Huynh-Dinh T. Lipophilic glycosyl phosphotriester derivatives of AZT: synthesis, NMR transmembrane transport study, and antiviral activity. J. Med. Chem. 34:1991;1830-1837.
11. Kuipers M.E., Swart P.J., Hendriks M.M., Meijer D.K. Optimization of the reaction conditions for the synthesis of neoglycoprotein-AZT-monophosphate conjugates. J. Med. Chem. 38:1995;883-889.
12. Piantadosi C, Marasco CJ Jr. Morris-Natshke et al. Synthesis and evaluation of novel ether lipid nucleoside conjugates anti-HIV-1 activity. J Med Chem 1991;34:1408-14
13. Rosowsky A., Fu H., Pai N., Mellors J., Richman D.D., Hostetler K.Y. Synthesis and in vitro activity of long-chain 5′-O-[(alkoxycarbonyl)phosphinyl]-3′-azido-3′- deoxythymidines against wild-type and AZT and foscarnet-resistant strains of HIV-1. J. Med. Chem. 40:1997;2482-2490.
14. Seki T., Kawaguchi T., Juni K. Enhanced delivery of zidovudine through rat and human skin via ester prodrugs. Pharm. Res. 7:1990;948-952.
15. Tan X., Chu C., Boudinot D. Development and optimization of anti-HIV nucleoside analogs and prodrugs: a review of their cellular pharmacology, structure-activity relationships and pharmacokinetics. Adv. Drug Deliv. Rev. 39:1999;117-151.
16. Vlieghe P., Bihel F., Clerc T., et al. New 3′-azido-3′-deoxythymidin-5′-yl O-(omega-hydroxyalkyl) carbonate prodrugs: synthesis and anti-HIV evaluation. J. Med. Chem. 44:2001;777-786.
17. Motura M.I., Salomón H., Moroni G.N., Wainberg M., Briñón M.C. Synthesis, lipophilicity and anti HIV activity of a new brominated analogue of zidovudine. Nucleos. Nucleot. 18:1999;337-351.
18. Motura MI, Moroni GN, Teijeiro SA, Salomón H, Briñón MC. 3′-Azido-3′-deoxy-5′-O-isonicotinoylthymidine, a new prodrug of zidovudine. Synthesis, solid state characterization and anti HIV-1 activity. Nucleos Nucleot Nucleic Acids, 2002;21:231-40.
19. Teijeiro S.A., Moroni G.N., Motura M.I., Briñón M.C. Lipophilic character of pyrimidinic nucleoside derivatives: correlation between shake flask, chromatographic (RP-TLC and RP-HPLC) and theoretical methods. J. Liq. Chrom. Rel. Technol. 23:2000;855-872.
20. Moroni GM, Bogdanov PM, Briñón MC. Synthesis and in vitro antibacterial activity of novel 5′-O-analogue derivatives of zidovudine as potential prodrugs. Nucleos Nucleot Nucleic Acids, 2002;21:217-30.
21. Quevedo M.A., Moroni G.N., Briñón M.C. Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. Biochem. Biophys. Res. Commun. 288:(4):2001;954-960.
22. Turk G, Moroni GN, Pampuro S, Briñón MC, Salomón H. Antiretroviral Activity and Cytotoxicity of Three Novel AZT Derivatives. The 1st IAS conference on HIV pathogenesis and treatment July 8-11, 2001, Buenos Aires, Argentina, Poster No. 243.
23. Skehan P., Storeng R., Scudiero D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;197-202.